Radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma: A prospective controlled trial.

Wen, Zhenyu; Wang, Junxiao; Tu, Bo; Liu, Yane; Yang, Yuqing; Hou, Li; Yang, Xiang; Liu, Xiaoyan; Xie, Hui

Wen, Zhenyu; Wang, Junxiao; Tu, Bo; Liu, Yane; Yang, Yuqing; Hou, Li; Yang, Xiang; Liu, Xiaoyan; Xie, Hui.

Affiliation

Wen Z; Department of Public Health, Jilin University, Jilin, China.
Wang J; Aerospace Medical Center, Aerospace Center Hospital, Beijing, China.
Tu B; Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Liu Y; Department of Public Health, Jilin University, Jilin, China.
Yang Y; Department of Public Health, Jilin University, Jilin, China.
Hou L; Department of Oncology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Yang X; Department of Oncology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Liu X; Department of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Xie H; Department of Oncology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.

Cancer Med ; 12(20): 20311-20320, 2023 10.

Article de En | MEDLINE | ID: mdl-37814921

Sujet(s)
Mots clés

anti-PD-1; prospective study; radiofrequency ablation; recurrent hepatocellular carcinoma; toripalimab

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Carcinome hépatocellulaire / Ablation par radiofréquence / Tumeurs du foie Limites: Female / Humans / Male / Middle aged Langue: En Journal: Cancer Med Année: 2023 Type de document: Article Pays d'affiliation: Chine Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google